FDA Clears MannKind’s Furoscix ReadyFlow — Company Raises $50M to Cover Milestone Payment
Following FDA clearance of Furoscix ReadyFlow for heart failure and CKD edema, MannKind secures $50 million to fund the $45M milestone payment.
/ 8 items
#MNKD↓
No More Shots for Kids! FDA Approves Inhaled Afrezza 6+
The FDA has just approved MannKind’s Afrezza—the first inhaled insulin for children aged 6 and older with Type 1 and Type 2 diabetes.
United Therapeutics Unveils Tresmi: The "Category Killer" Inhaler Set to End Coughing Woes in PAH and ILD
United Therapeutics announces Tresmi, a revolutionary soft mist inhaler version of Treprostinil that cuts coughing side effects by up to 90%. Planned approval filing this year and launch next year, impacting strategic partner MannKind's stock.
FDA Approves New Dosing Guidelines for Afrezza Inhaled Insulin
MannKind (MNKD) receives FDA approval for updated Afrezza dosing recommendations, making it easier for patients to switch from insulin injections to inhaled insulin therapy.
Key Pharma Stock Updates: Merck, BeOne, MeiraGTx, MannKind, and Fulcrum
Wells Fargo upgrades Merck to Overweight; Truist and H.C. Wainwright initiate coverage on BeOne Medicines, MeiraGTx, MannKind, and Fulcrum with Buy ratings and promising price targets.
MannKind Ends Phase 3 ICoN-1 Trial for Nebulized Clofazimine After Futility Review
MannKind Corporation discontinues its Phase 3 ICoN-1 trial for nebulized clofazimine (MNKD-101) in NTM lung disease after futility analysis shows no efficacy. The company will focus on developing its dry powder version, MNKD-102.